Inthelia Therapeutics BLUE KNIGHT™ QuickFire Challenge awardee (IMAGE)
Caption
RCSI spin-out company Inthelia Therapeutics has been named as an awardee of the international BLUE KNIGHT™ QuickFire Challenge: Next-Generation Preparedness Solutions related to the company’s work on non-antibiotic therapies for sepsis. The award recognises the potential to develop a biomarker-led treatment for early sepsis, a leading cause of hospital deaths. Inthelia’s innovation may also contribute to combating the growing threat of antibiotic resistance. Pictured with their BLUE KNIGHT™ QuickFire Challenge award are co-founders of RCSI spin-out company Inthelia Therapeutics (l-r) Prof. Steve Kerrigan, RCSI School of Pharmacy and Biomolecular Sciences and Dr Ivan Coulter, CEO of Inthelia. Blue Knight is a joint initiative between Johnson & Johnson Innovation LLC and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.
Credit
Maxwell Photography
Usage Restrictions
None
License
Original content